Literature DB >> 17401717

Seronegative Lyme neuroborreliosis in a patient on treatment for chronic lymphatic leukemia.

T Harrer1, W Geissdörfer, C Schoerner, E Lang, G Helm.   

Abstract

We report on a patient who developed seronegative Lyme neuroborreliosis complicating chemotherapy for chronic lymphatic leukemia. After the fifth cycle of chemotherapy (FCR: fludarabine, cyclophosphamide, rituximab and prednisone) the 63-year-old patient developed night sweat, arthralgia in elbows, wrists, proximal interphalangeal joints (PIPs) and strong neuropathic pain in both legs, followed by paresthesia and hypesthesia in the feet, arms and face. Laboratory analysis revealed an elevated C-reactive protein (CRP), a slight elevation of liver enzymes and decreased IgG levels. Cerebrospinal fluid (CSF) analysis showed a lymphomononuclear pleocytosis and an elevation of protein. A broad diagnostic work-up was negative including a negative Borrelia IgG and IgM ELISA. The patient did not remember recent tick bites, but after specific questioning he recollected a transient erythema on his leg developing just before the start of the last cycle of chemotherapy. As the combination of neuropathic pain and arthralgia, the transient erythema and the lymphomononuclear pleocytosis raised the suspicion of Lyme neuroborreliosis, the patient was treated for 3 weeks with ceftriaxone. On therapy all symptoms resolved and CRP normalized. Retrospective PCR analysis of a CSF sample confirmed the clinical diagnosis by detecting Borrelia garinii DNA. This case demonstrates that in immunosuppressed patients borrelial serology may be negative and that additional diagnostic approaches (including tests for direct Borrelia detection) may be needed to demonstrate borrelial infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401717     DOI: 10.1007/s15010-007-6121-0

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  Lyme neuroborreliosis in a patient treated with TNF-alpha inhibitor.

Authors:  Maja Ivartnik Merkac; Janez Tomazic; Franc Strle
Journal:  Infection       Date:  2015-04-29       Impact factor: 3.553

2.  Seronegative lyme neuroborreliosis in a patient using rituximab.

Authors:  Willemijn Alexandra van Dop; Marie-José Kersten; Bob de Wever; Joppe Willem Hovius
Journal:  BMJ Case Rep       Date:  2013-02-14

Review 3.  Laboratory Diagnosis of Lyme Borreliosis.

Authors:  John A Branda; Allen C Steere
Journal:  Clin Microbiol Rev       Date:  2021-01-27       Impact factor: 26.132

Review 4.  Tick-borne pathogen - reversed and conventional discovery of disease.

Authors:  Ellen Tijsse-Klasen; Marion P G Koopmans; Hein Sprong
Journal:  Front Public Health       Date:  2014-07-07

5.  Common and uncommon neurological manifestations of neuroborreliosis leading to hospitalization.

Authors:  Philipp Schwenkenbecher; Refik Pul; Ulrich Wurster; Josef Conzen; Kaweh Pars; Hans Hartmann; Kurt-Wolfram Sühs; Ludwig Sedlacek; Martin Stangel; Corinna Trebst; Thomas Skripuletz
Journal:  BMC Infect Dis       Date:  2017-01-21       Impact factor: 3.090

6.  Erythema Migrans: Course and Outcome in Patients Treated With Rituximab.

Authors:  Vera Maraspin; Petra Bogovič; Tereza Rojko; Eva Ružić-Sabljić; Franc Strle
Journal:  Open Forum Infect Dis       Date:  2019-06-19       Impact factor: 3.835

Review 7.  Immunoserological Diagnosis of Human Borrelioses: Current Knowledge and Perspectives.

Authors:  Emilie Talagrand-Reboul; Alice Raffetin; Pierre Zachary; Benoît Jaulhac; Carole Eldin
Journal:  Front Cell Infect Microbiol       Date:  2020-05-19       Impact factor: 5.293

8.  Neuroborreliosis with Unusual Presentation: A Case Report.

Authors:  Salman Khan; Gurjaspreet K Bhattal; Nikhil H Shah; Jorge Lascano; Apurwa Karki
Journal:  Cureus       Date:  2019-09-25

9.  Case report: persistently seronegative neuroborreliosis in an immunocompromised patient.

Authors:  A Wagemakers; M C Visser; B de Wever; J W Hovius; N W C J van de Donk; E J Hendriks; L Peferoen; F F Muller; C W Ang
Journal:  BMC Infect Dis       Date:  2018-08-02       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.